进食对Fibroscan检测肝脏受控衰减参数的影响*

doi:10.3969/j.issn.1672-5069.2016.05.011

实用肝脏病杂志 ›› 2016, Vol. 19 ›› Issue (5): 553-556.doi: 10.3969/j.issn.1672-5069.2016.05.011

进食对Fibroscan检测肝脏受控衰减参数的影响^*

陈光榆, 潘勤, 沈峰, 卢加发, 章瑞南, 朱婵艳, 孙婉璐, 曾静, 吴佳瑜, 范建高

200092 上海市上海交通大学附属新华医院临床研究中心（陈光榆）; 消化内科脂肪肝诊治中心（潘勤,沈峰,卢加发,章瑞南,朱婵艳,孙婉璐,曾静,陈一铭,吴佳瑜,范建高）

收稿日期:2016-03-20 出版日期:2016-09-10 发布日期:2016-10-12
通讯作者: 范建高,E-mail: fattyliver2004@126.com
作者简介:陈光榆,女,39岁,医学博士,主治医师
基金资助:
国家973计划项目（编号：2012CB517501）; 国家自然科学基金资助项目（编号：81070322/81270491）; 上海市卫生系统优秀学科带头人计划项目（编号：XBR2011007）; 中国肝炎防治基金会王宝恩肝纤维化研究基金资助项目（编号：XJS20120501）; 上海交通大学医学院附属新华医院院长基金项目（编号12QYJ05）

Effect of food intake on the accruacy of controlled attenuation parameter in diagnosis of patients with liver steatosis by Fibroscan

Chen Guangyu, Pan Qin, Shen Feng, et al.

Center For The Study of Fatty Liver Diseases,Department of Gastroenterology,Xinhua Hospital,Jiao Tong University School of Medicine,Shanghai 200092,China

Received:2016-03-20 Online:2016-09-10 Published:2016-10-12

摘要/Abstract

摘要： 目的探讨进食对Fibroscan检测肝脏受控衰减参数（CAP值）及其诊断脂肪肝的影响。方法使用Fibroscan测量10例志愿者【7名健康人和3名经B超诊断的脂肪肝患者,平均年龄29岁（21~39）岁;体质指数为（19.83~29.70） kg/m²,平均为（22.7±3.13） kg/m²）】空腹（CAP0）、进食后30 min （CAP30）、120 min （CAP120）和次日空腹（CAP02）肝脏CAP值的差异,并比较空腹与进食后CAP值诊断脂肪肝的准确性。结果受检者CAP0、CAP30、CAP120和CAP02分别为（227.8±59.5） dB/m、（244.9±42.1） dB/m、（241.1±51.4） dB/m和（245.7±49.4） dB/m,差异无统计学意义（H=0.62,P=0.89）;空腹（空腹和次日空腹）与餐后（餐后30 min和120 min）CAP值差值比较,差异也无统计学意义（Z=-1.37,P=0.17）,但空腹与餐后检测诊断脂肪肝的误诊率分别为5%和15%（x²=0.28,P=0.59）。结论进食对Fibroscan检测CAP值的结果影响不显著,但或可增加诊断脂肪肝的误诊率。

关键词: 脂肪肝, 受控衰减参数, 瞬时弹性记录仪, 进食

Abstract: Objective To investigate the effect of food intake on the accrracy of fatty liver by the assessment of controlled attenuation parameter（CAP） in patients with liver steatosis. Methods Hepatic CAP values were measured by Fibroscan in 10 volunteers including 7 healthy subjects and 3 with fatty liver with average age of 29 （21~39） yr and body mass index of （22.7±3.13） kg/m²,and the CAPs were obtained at fasting （CAP0）,30 minutes （CAP30）,120 minutes （CAP120） after a standard meal,and the next day of fasting （CAP02）. Results The CAP0,CAP30,CAP120 and CAP02 were（227.8±59.5） dB/m,（244.9±42.1） dB/m,（241.1±51.4） dB/m and （245.7±49.4） dB/m,respectively,with no statistical differences between them（H=0.62,P=0.89）;there was no statistical differences between CAP at fasting state（baseline and the next day fasting）,and at the post-prandial state（30,120 minutes,Z=-1.37,P=0.17）,while the misdiagnosis rates were 5% and 15%,respectively（x²=0.28,P=0.59）. Conclusion The effect of eating on Fibroscan detection of CAP value is not significant,but might increase the rate of misdiagnosis of fatty liver to some extent.

陈光榆, 潘勤, 沈峰, 卢加发, 章瑞南, 朱婵艳, 孙婉璐, 曾静, 吴佳瑜, 范建高. 进食对Fibroscan检测肝脏受控衰减参数的影响^*[J]. 实用肝脏病杂志, 2016, 19(5): 553-556.

Chen Guangyu, Pan Qin, Shen Feng, et al.. Effect of food intake on the accruacy of controlled attenuation parameter in diagnosis of patients with liver steatosis by Fibroscan[J]. JOURNAL OF PRACTICAL HEPATOLOGY, 2016, 19(5): 553-556.

参考文献

[1] Sasso M,Miette V,Sandrin L,et al. The controlled attenuation parameter（CAP）:a novel tool for the non-invasive evaluation of steatosis using Fibroscan. Clin Res Hepatol Gastroenterol,2012,36:13-20.
[2] Chin JL,Farrelly A,Chan G,et al. Liver stiffness changes during meal times. Hepatology,2014,60:432.
[3] Lemoine M,Shimakawa Y,Njie R,et al. Food intake increases liver stiffness measurements and hampers reliable values in patients with chronic hepatitis B and healthy controls:the PROLIFICA experience in the Gambia. Aliment Pharmacol Ther,2014,39:188-196.
[4] Arena U,Lupsor Platon M,Stasi C,et al. Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution. Hepatology,2013,58:65-72.
[5] Tsochatzis EA,Burroughs AK. Liver stiffness measurements increase after meal ingestion-an important step towards standardization. Ann Hepatol,2014,97:1033-1039.
[6] Mederacke I,Bahr MJ. Liver stiffness after meal intake at different stages of fibrotic evolution. Hepatology,2014,59:734-735.[7] Mederacke I,Wursthorn K,Kirschner J,et al. Food intake increases liver stiffness in patients with chronic or resolved hepatitis C virus infection. Liver Int,2009,29:1500-1506.
[8] Tapper EB,Castera L,Afdhal NH. FibroScan （vibration-controlled transient elastography）:where does it stand in the United States practice. Clin Gastroenterol Hepatol,2015,13:27-36.
[9] 范建高. 中国脂肪肝防治指南（科普版）. 上海:上海科学技术出版社,2015:47-49.
[10] 韩馥缦,傅妹伢,舒建昌,等. 影响瞬时弹性成像术检测肝纤维化的相关因素分析. 胃肠病学和肝病学杂志,2015,24:264-266.
[11] Berzigotti A,Abraldes JG,Bosch J. Regarding “Liver stiffness is influenced by a standardized meal in patients with chronic hepatitis C virus at different stages of fibrotic evolution”. Hepatology, 2014,59:350-351.
[12] Tangpradabkiet W,Praneenararat S,Chamroonkul N,et al. Influence of meal intake on liver stiffness in patients with chronic hepatitis B and C. J Med Assoc Thai,2014,97:1033-1039.
[13] 肝脏硬度评估小组. 瞬时弹性成像技术诊断肝纤维化专家意见. 中华肝脏病杂志,2013,21:420-424.
[14] 曹建彪,陈永平,成军,等. 瞬时弹性成像技术（TE）临床应用专家共识（2015年）.中国肝脏病杂志（电子版）,2015,7:12-18.
[15] 傅玉娟,祁婷婷,熊鸣,等. 进食及进水早期降低对Fibroscan实施受控衰减参数的短期影响. 肝脏,2015,20:517-521.
[16] Barone M,Iannone A,Brunetti ND,et al. Liver stiffness and portal blood flow modifications induced by a liquid meal consumption:pathogenetic mechanisms and clinical relevance. Scand J Gastroenterol,2015,50:560-566.
[17] Berzigotti A,De Gottardi A,Vukotic R,et al. Effect of meal ingestion on liver stiffness in patients with cirrhosis and portal hypertension. PLoS One,2013,8:e58742.
[18] Alvarez D,Orozco F,Mella JM,et al. Meal ingestion markedly increases liver stiffness suggesting the need for liver stiffness determination in fasting conditions. Gastroenterol Hepatol,2015,38:431-435.

进食对Fibroscan检测肝脏受控衰减参数的影响^*

Effect of food intake on the accruacy of controlled attenuation parameter in diagnosis of patients with liver steatosis by Fibroscan

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价

[1]	中国研究型医院学会肝病专业委员会, 中国医师协会脂肪性肝病专家委员会. 脂肪性肝病诊疗规范化的专家建议（2019年修订版）[J]. 实用肝脏病杂志, 2019, 22(6): 787-792.
[2]	谢晓, 刘婷, 董志霞, 夏幼辰, 张启迪, 曲颖, 蔡晓波, 徐铭益, 陆伦根. FibroTouch检测肝脏受控衰减参数对肝脂肪变的诊断价值分析^*[J]. 实用肝脏病杂志, 2019, 22(4): 526-529.
[3]	范建高. 2018年《实用肝脏病杂志》精彩回顾[J]. 实用肝脏病杂志, 2019, 22(1): 1-3.
[4]	黄娇凤, 林苏, 王明芳, 黄映芳, 熊美连, 朱月永. 恩替卡韦治疗慢性乙型肝炎合并非酒精性脂肪性肝病患者疗效及其对肝组织脂肪变的影响^*[J]. 实用肝脏病杂志, 2018, 21(6): 863-867.
[5]	董雪莲, 张文均. 肝脏受控衰减参数检测早期无创发现代谢综合征人群价值分析^*[J]. 实用肝脏病杂志, 2018, 21(6): 868-871.
[6]	浦永兰, 陈源文, 范建高. 麦胶性肠病并发非酒精性脂肪肝1例报告[J]. 实用肝脏病杂志, 2018, 21(6): 981-982.
[7]	中华医学会肝病学分会脂肪肝和酒精性肝病学组, 中国医师协会脂肪性肝病专家委员会. 非酒精性脂肪性肝病防治指南（2018年更新版）[J]. 实用肝脏病杂志, 2018, 21(2): 177-186.
[8]	张志华, 顾天翊, 陈柳莹, 陆伦根. 门冬氨酸鸟氨酸治疗脂肪肝疗效Meta分析[J]. 实用肝脏病杂志, 2018, 21(2): 233-236.
[9]	陆检英，郑国银，彭浩，李欢，周海燕，张高彬. 甘枣宁颗粒治疗非酒精性脂肪肝临床疗效及安全性分析[J]. 实用肝脏病杂志, 2017, 20(6): 709-712.
[10]	王倩,郭萍. Fibroscan联合人体测量学指标诊断非酒精性脂肪性肝病效能分析[J]. 实用肝脏病杂志, 2017, 20(6): 754-755.
[11]	李笠, 梁学亚. 水飞蓟宾葡甲胺联合多烯磷脂酰胆碱治疗酒精性脂肪肝患者初步临床研究[J]. 实用肝脏病杂志, 2017, 20(4): 412-415.
[12]	孙长贵，曾静，孙婉璐，陈光榆，潘勤，范建高. 非酒精性脂肪性肝病患者估算的肾小球滤过率的变化及其影响因素分析*[J]. 实用肝脏病杂志, 2017, 20(2): 165-170.
[13]	杨秀珍, 耿爱文, 肖丽, 咸建春. 慢性乙型肝炎合并脂肪肝临床与肝组织病理学分析^*[J]. 实用肝脏病杂志, 2017, 20(1): 101-102.
[14]	曾静, 陈光榆, 潘勤, 孙婉璐, 顾立飞, 颜士岩, 孙超, 徐正婕, 范建高. FibroTouch检测脾脏与肝脏受控衰减参数的相关性及影响因素分析^*[J]. 实用肝脏病杂志, 2016, 19(4): 445-450.
[15]	郭灿, 曾莉. 疏肝健脾方含药血清对酒精性损伤HepG2细胞脂肪变性的保护作用[J]. 实用肝脏病杂志, 2016, 19(2): 160-163.